Asthma

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

A review shows that real-world persistence with asthma biologics depends not only on efficacy, but also on patient perceptions and mental health.

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.

Depemokimab-ulaa is the first and only ultra-long-acting biologic with twice-yearly dosing for patients with severe asthma with an eosinophilic phenotype.

A review in Wichita, Kansas, shows asthma-related emergency visits spike during storms, underscoring the importance of weather-based asthma action plans for at-risk patients.

Study shows house dust mite SLIT therapy is safe in children with allergic asthma, though COVID-19–related drops in exacerbations impacted the primary endpoint.

November 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

PR was seen to reduce FeNO, a biomarker of type 2 inflammation, in a new study.

Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.

However, a related editorial from University of Rome was quick to point out possibly sizable placebo effects in the trial.

Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Rogers discusses the evolving definition of clinical remission in asthma and why clinicians must set higher treatment goals.

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The therapy is currently approved in almost 50 countries under the name Trimbow.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.